Takeda Doses First Patient in Phase I Anemia Trial
Posted on: Friday, 25 January 2008, 09:00 CST
Takeda Pharmaceutical and Affymax have reported that Takeda has dosed the first patient in the US clinical trial of the investigational new drug, Hematide, for the treatment of anemia in cancer patients undergoing chemotherapy.
The multicenter, open-label, repeat dose clinical trial in chemotherapy induced anemia (CIA) will enroll approximately 100 non-small cell lung cancer, prostate or breast cancer patients who have relapsed or progressed after previous treatment and who are anemic and receiving a taxane-containing chemotherapy. Patients will be dosed every three weeks (Q3W) until four weeks after discontinuation of their chemotherapy regimen, the occurrence of dose limiting toxicity, documented disease progression, or change in chemotherapy regimen.
The trial will evaluate the safety, pharmacokinetics and preliminary efficacy of various doses of Hematide in the correction of anemia. Initial dosing in this trial is based on results from an earlier trial in a more heterogeneous population of cancer patients that was conducted by Affymax in Europe in 2006. This new US trial will aid in the selection of the appropriate dose or doses to be used in this more homogeneous patient population in additional later stage clinical trials.
Under the terms of the 2006 collaboration, Takeda and Affymax are jointly developing Hematide, and Affymax is now conducting a Phase III studies for the treatment of anemia in chronic renal failure patients in the US and Europe.
Source: Datamonitor
Related Articles
- Biomodels' Oral Mucositis Expertise Speeds FDA Approval for ActoGeniX's Phase 1b Trial of AGO13 in Cancer Patients
- Calando Doses First Patient in Phase I Cancer Study
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia
- Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients With Anemia Due to Chemotherapy at FDA ODAC Meeting
- Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
- Affymax Begins a Phase 2 Trial of Hematide(TM) for Treatment of Anemia in Patients With Chronic Kidney Disease on Hemodialysis
- Regeneron's VEGF Trap Demonstrates Positive Preliminary Results From Single-Agent Phase 1 Trial in Patients With Advanced Cancer; Results Presented at ASCO Annual Meeting on May 16, 2005
- Australian Cancer Technology Reports Doubling of Mean Survival Time in Patients With Pancreatic Cancer Using RP101 With Chemotherapy Treatment
- Palliative Treatment of Painful Disseminated Bone Metastases With ^Sup 186^Rhenium-HEDP in Patients With Lung Cancer
 |
 |
User Comments (0)
RSS Feeds